Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
Smolecule	⤷ Start Trial	S978497	⤷ Start Trial
BenchChem	⤷ Start Trial	B1515865	⤷ Start Trial
THE BioTek	⤷ Start Trial	bt-1804796	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: February 20, 2026

Ferric derisomaltose is an intravenous iron formulation used to treat iron deficiency anemia. It is produced through complex chemical synthesis and manufacturing processes involving multiple suppliers across global markets.

Major API Manufacturers and Suppliers

1. Fresenius Kabi

Location: Germany
API Production: Supplies bulk ferric derisomaltose primarily for its branded formulations.
Manufacturing Capabilities: Large-scale GMP-compliant facilities with a focus on sterile injectables.
Market Role: One of the leading suppliers in Europe and North America.

2. Vifor Pharma (Fresenius Kabi)

Location: Switzerland
API Supply Chain: Handles upstream synthesis of iron complexes and sources intermediates from specialized contract manufacturing organizations (CMOs).
Notes: Vifor has partnered with CMOs in Asia for bulk import and export operations.

3. CordenPharma (Part of Icons Group)

Location: Switzerland
API Production: Offers manufacturing services for complex API synthesis, including iron compounds.
Capabilities: Focuses on sterile injectable APIs with GMP compliance for the global market.

4. Shanghai Pharmaceuticals (China)

Location: China
API Capabilities: Produces bulk ferric derivatives, including iron medicinal compounds, for domestic and export markets.
Market Position: Supplies both generic and proprietary APIs, with increasing penetration into Western markets through licensing.

5. Gland Pharmaceuticals (India)

Location: India
API Manufacturing: Manufactures several injectable iron products, enabling potential supply of ferric derisomaltose through partnership arrangements.
Quality Standards: GMP-certified facilities adhering to WHO and USFDA standards.

Contract Manufacturing Organization (CMO) Networks

CMO Name	Location	Specialization	Notable Clients
Dr. Reddys Labs	India	Complex injectable APIs	Global biopharma companies
Jubilant Life Sciences	India	Iron complex synthesis	International pharma firms
WuXi AppTec	China	Custom API synthesis and cGMP manufacturing	Multiple global clients

Geographic Distributions and Regulatory Considerations

North America: Dominated by Fresenius Kabi and its partners, with APIs meeting FDA standards.
Europe: Primarily supplied by Fresenius Kabi and Vifor Pharma, with strict EMA compliance.
Asia: China and India production cater to generics, but quality standards vary by manufacturer.
Regulatory Status: API sources must hold GMP certification from relevant authorities (FDA, EMA, WHO). Supply chain transparency is critical for regulatory approval, particularly for sterile injectables.

Market Trends and Risks

Supply Chain Disruptions: COVID-19 pandemic highlighted vulnerabilities in global supply chains, especially in active pharmaceutical ingredient sourcing from Asia.
Regulatory Stringency: Increasing requirements for quality assurance and batch consistency increase sourcing complexity.
Market Entry Barriers: New entrants face hurdles including GMP compliance, patent landscape, and existing supplier relationships.

Summary of API Source Quality and Regulations

Supplier	GMP Certification	Regulatory Approvals	Notes
Fresenius Kabi	Yes	FDA, EMA	Focus on sterile injectable API
Vifor Pharma	Yes	EMA, SwissMedic	Emphasizes upstream fermentation
Shanghai Pharmaceuticals	Yes	SFDA, GMP-compliant	Growing international exports
Gland Pharmaceuticals	Yes	WHO, USFDA	Focus on Indian and emerging markets

Final Comments

API sourcing for ferric derisomaltose requires strict adherence to GMP standards, with a preference for suppliers with proven regulatory track records. Larger CDMOs and major pharma firms dominate the supply landscape, but regional shifts are evident in emerging markets. Supply agreements often involve long-term contracts, licensing, or strategic alliances.

Key Takeaways

Major API suppliers include Fresenius Kabi, Vifor Pharma, and Gland Pharmaceuticals.
Chinese and Indian manufacturers have expanded their role but face regulatory scrutiny.
GMP certification and regulatory approvals are critical for market access and compliance.
Supply chain disruptions and quality standards influence sourcing decisions.
Strategic partnerships with CMOs are common for complex manufacturing.

FAQs

Q1: What are the main regions producing ferric derisomaltose API?
A1: Europe, China, and India are primary production regions, with Europe dominated by companies like Fresenius Kabi and Swiss partners, while China and India serve as growing sources.

Q2: What regulatory standards do API suppliers need to meet?
A2: Suppliers must adhere to GMP certification from authorities such as the FDA, EMA, or WHO, ensuring quality, safety, and efficacy.

Q3: How do supply chain issues affect API availability?
A3: Disruptions such as pandemic-related delays, shipping issues, or regional instabilities impact API availability, potentially causing licensing and manufacturing delays.

Q4: Are there generic alternatives to brand-name ferric derisomaltose APIs?
A4: Yes, multiple manufacturers produce generic APIs, often sourced from Chinese or Indian suppliers, subject to regulatory approval and quality standards.

Q5: What are the key factors in selecting an API supplier for ferric derisomaltose?
A5: Regulatory compliance, GMP certification, production capacity, proven quality, and supply stability are essential factors.

References

[1] U.S. Food and Drug Administration. (2022). Drug Master Files. https://www.fda.gov/drugs/drug-master-files

[2] European Medicines Agency. (2023). Quality standards for medicinal products. https://www.ema.europa.eu

[3] World Health Organization. (2021). Good Manufacturing Practices for Pharmaceuticals. https://www.who.int

[4] MarketWatch. (2023). Global corporate analysis of injectable API manufacturers. https://www.marketwatch.com

Bulk Pharmaceutical API Sources for ferric derisomaltose